106 related articles for article (PubMed ID: 38743828)
1. Molecular Deciphering of Colorectal Cancer: Exploring Molecular Classifications and Analyzing the Interplay among Molecular Biomarkers MMR/MSI, KRAS, NRAS, BRAF and CDX2 - A Comprehensive Literature Review.
Ilie-Petrov AC; Cristian DA; Diaconescu AS; Chitul A; Blajin A; Popa A; Mandi DM; Negreanu R; Vieru C; Vrîncianu R; Ardeleanu CM
Chirurgia (Bucur); 2024 Apr; 119(2):136-155. PubMed ID: 38743828
[No Abstract] [Full Text] [Related]
2. Evaluation of
Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
[TBL] [Abstract][Full Text] [Related]
3. Loss of SATB2 and CDX2 expression is associated with DNA mismatch repair protein deficiency and BRAF mutation in colorectal cancer.
Li J; Zeng Q; Lin J; Huang H; Chen L
Med Mol Morphol; 2024 Mar; 57(1):1-10. PubMed ID: 37583001
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
[TBL] [Abstract][Full Text] [Related]
5. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
7. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
8. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
[TBL] [Abstract][Full Text] [Related]
10. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.
Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K
Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883
[TBL] [Abstract][Full Text] [Related]
13. Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study.
Baba O; Bidikian A; Mukherji D; Shamseddin A; Temraz S; Fakhruddin N; Khazzouh M; Ghizzawi D; Abdel Khalek R; Zaatari G; Mahfouz R
Gene; 2022 Aug; 834():146646. PubMed ID: 35680020
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological and molecular evaluation of BRAF, KRAS, NRAS genes and MSI in the development of colorectal cancer.
Paula Simedan Vila A; Helena Rodrigues G; Leite Marzochi L; Garcia de Oliveira-Cucolo J; Lívia Silva Galbiatti-Dias A; Felipe Maciel Andrade R; de Santi Neto D; Gomes Netinho J; Castiglioni L; Cristina Pavarino É; Maria Goloni-Bertollo E
Gene; 2023 Jun; 870():147395. PubMed ID: 36990254
[TBL] [Abstract][Full Text] [Related]
15. Epidemiological and clinicopathological features of KRAS, NRAS, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer.
Wang W; Wang R; Han X; Zhang W; Zhu L; Gu Y
Medicine (Baltimore); 2024 Apr; 103(14):e37693. PubMed ID: 38579072
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
[TBL] [Abstract][Full Text] [Related]
17. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition.
Yamazaki K; Taniguchi H; Yoshino T; Akagi K; Ishida H; Ebi H; Nakatani K; Muro K; Yatabe Y; Yamaguchi K; Tsuchihara K
Cancer Sci; 2018 Jun; 109(6):2074-2079. PubMed ID: 29873882
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
19. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
20. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
